-
Sector Analysis
Psoriatic Arthritis Epidemiology Analysis and Forecast to 2033
Psoriatic Arthritis Report Overview In 2023, there were 1,547,313 diagnosed prevalent cases of psoriatic arthritis across the 7MM. Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy that may be progressive and can lead to severe joint damage and disability. The disease is considered rare in the general population, but PsA affects up to 30% of people with psoriasis. The psoriatic arthritis market research report provides an overview of the risk factors, comorbidities, and global trends of psoriatic arthritis in the...
-
Thematic Analysis
Cell and Gene Therapies in Gastrointestinal Disorders - Therapeutic Analysis, Treatment Options, Pricing and Reimbursement and Future Market
Currently, there are only two cell and gene therapies (CGTs) on the market across all gastroenterology (GI) indications. Anterogen’s Cupistem, indicated for the treatment of anal fistula in adult patients, was the first adipose tissue-derived mesenchymal stem cell (ASC) asset to receive approval in the GI market in Japan, 2012. This was followed by Takeda Pharmaceutical’s Alofisel (darvadstrocel), which received approval from the European Medicines Agency (EMA) in 2018 and from Japan’s Pharmaceuticals and Medical Devices Agency (PDMA) in 2021. However,...
-
Sector Analysis
Atopic Dermatitis (AD) Epidemiology Analysis and Forecast to 2033
Atopic Dermatitis (AD) Report Overview In the 7MM, there were 42,015,612 diagnosed prevalent cases of AD in 2023. The diagnosed prevalent cases of AD will register an AGR of less than 1% during 2023-2033. Atopic dermatitis (AD) is a heterogenous and chronic inflammatory skin condition characterized by the remission and relapse of skin lesions and pruritus. Severe AD can impact patients’ daily life and cause sleep disturbances, anxiety, depression, and impaired quality of life. Atopic Dermatitis (AD) Market Outlook, 2023-2033...
-
Sector Analysis
Hepatitis C Therapeutics Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Hepatitis C Therapeutics . GlobalData epidemiologists estimate that there will be 25.16 million diagnosed prevalent cases of Hepatitis C (HCV) infection in 2024, which is expected to increase slightly to 25.84 million diagnosed prevalent cases by 2029. The HCV treatment landscape has experienced successive waves of revolutionary change and is now dominated by direct-acting antivirals (DAAs). The HCV pipeline holds 68 molecules, with one asset in...
-
Sector Analysis
Asthma and Severe Asthma Epidemiology Analysis and Forecast to 2033
] Asthma and Severe Asthma Report Overview In the 8MM, there were 56,552,679 12-month diagnosed prevalent cases of asthma in 2023. The diagnosed prevalent cases will register an AGR of less than 1% during 2023-2033. Asthma is a common lung condition characterized by the narrowing and swelling of the lungs' airways and the production of excess mucus. Common asthma symptoms include wheezing, breathlessness, chest tightness, and coughing at night or early in the morning. Asthma and Severe Asthma Market Outlook,...
-
Sector Analysis
Gout Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Gout Market Report Overview The gout market across the 7MM (the US, France, Germany, Italy, Spain, the UK, and Japan) was valued at $4.63 billion in 2022 and the market will grow at a CAGR of more than 9% from 2022 to 2032. The market growth is attributed to the entrance of novel urate-lowering therapy (ULTs) which will increase the treatment options for more challenging and severe types of gout. This, in turn, will also accelerate the patient pool. The...
-
Thematic Analysis
Pharmaceutical Review Designations - Trends and Industry Insights
This report investigates review designations in the pharmaceutical industry from the standpoint of drug development. It provides an in- depth review of the history and available designations alongside high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern teh impact these designations have had on the market and on the drug products themselves.
-
Sector Analysis
Schizophrenia in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2031
Schizophrenia Market Report Overview The schizophrenia market size across the 7MM was $8.4 billion in 2021 and will achieve a CAGR of more than 7% during 2021-2031. The market growth is attributed to the launch of 11 new pipeline products, all of which will have higher ACOTs compared with the cost of the most commonly used antipsychotic treatments, which are highly genericized. Schizophrenia Market Outlook, 2021-2031 ($ Billion) Buy the Full Report for More Insights on the Schizophrenia Market Report...
-
Likelihood of Approval and Phase Transition Success Rate Model - Pucotenlimab in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pucotenlimab in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pucotenlimab in Non Muscle...
-
Likelihood of Approval and Phase Transition Success Rate Model - (Mirabegron + Tamsulosin Hydrochloride) in Benign Prostatic Hyperplasia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Mirabegron + Tamsulosin Hydrochloride) in Benign Prostatic Hyperplasia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Mirabegron + Tamsulosin Hydrochloride) in Benign Prostatic...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.